Pharmacological Screening Using an FXN-EGFP Cellular Genomic Reporter Assay for the Therapy of Friedreich Ataxia

Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model

(2012) B. Tomassini et al.   HUMAN MOLECULAR GENETICS

FXN methylation predicts expression and clinical outcome in Friedreich ataxia

(2011) Marguerite V. Evans-Galea et al.   ANNALS OF NEUROLOGY

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model

(2011) Chiranjeevi Sandi et al.   NEUROBIOLOGY OF DISEASE

Long Range Regulation of Human FXN Gene Expression

(2011) Novita Puspasari et al.   PLoS One

Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000 mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects

(2010) Charles la Porte et al.   CLINICAL PHARMACOKINETICS

SIRT1 Activation by Small Molecules

(2010) Han Dai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit

(2010) Francesco Saccà et al.   MOVEMENT DISORDERS

Two New Pimelic Diphenylamide HDAC Inhibitors Induce Sustained Frataxin Upregulation in Cells from Friedreich's Ataxia Patients and in a Mouse Model

(2010) Myriam Rai et al.   PLoS One

PGC-1alpha Down-Regulation Affects the Antioxidant Response in Friedreich's Ataxia

(2010) Daniele Marmolino et al.   PLoS One

The dorsal root ganglion in Friedreich’s ataxia

(2009) Arnulf H. Koeppen et al.   ACTA NEUROPATHOLOGICA

Resveratrol is Not a Direct Activator of SIRT1 Enzyme Activity

(2009) Dirk Beher et al.   Chemical Biology & Drug Design

Chemical Probes Identify a Role for Histone Deacetylase 3 in Friedreich's Ataxia Gene Silencing

(2009) Chunping Xu et al.   CHEMISTRY & BIOLOGY

Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARγ pathway as a therapeutic target in Friedreich’s ataxia

(2009) Giovanni Coppola et al.   HUMAN MOLECULAR GENETICS

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers

(2009) Luis Almeida et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Diagnosis and treatment of Friedreich ataxia: a European perspective

(2009) Jörg B. Schulz et al.   Nature Reviews Neurology

PGC-1  is coupled to HIF-1 -dependent gene expression by increasing mitochondrial oxygen consumption in skeletal muscle cells

(2009) K. A. O'Hagan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PPAR-γ Agonist Azelaoyl PAF Increases Frataxin Protein and mRNA Expression. New Implications for the Friedreich’s Ataxia Therapy

(2008) Daniele Marmolino et al.   CEREBELLUM

Resveratrol: One molecule, many targets

(2008) Luciano Pirola et al.   IUBMB LIFE

Binding of Yeast Frataxin to the Scaffold for Fe-S Cluster Biogenesis, Isu

(2008) Tao Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Lateral-flow immunoassay for the frataxin protein in Friedreich’s ataxia patients and carriers

(2008) John H. Willis et al.   MOLECULAR GENETICS AND METABOLISM

Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: A clinical pilot trial

(2008) Sylvia Boesch et al.   MOVEMENT DISORDERS

HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse Model

(2008) Myriam Rai et al.   PLoS One

Drug Insight: antioxidant therapy in inherited ataxias

(2008) Massimo Pandolfo   Nature clinical practice. Neurology